Madrigal Pharmaceuticals Inc (MDGL)

[DMOST]

3 Top Stocks for Investing in Pharma's Next $35 Billion Market

Madrigal Pharmaceuticals: Fast climber

This biotech came out of nowhere to take a leading position in the NASH dash with solid data for MGL-3196 late last year. The company followed up in May with results that suggest it will give Ocaliva a challenge. During a mid-stage study, 27% of patients treated with MGL-3196 achieved NASH resolution versus just 6% of those treated with a placebo.

Intercept is months away from wrapping up Ocaliva's pivotal NASH trial, but Madrigal hasn't even started one yet. When Madrigal checked in last, management was still waiting for the FDA to sign off on the company's pivotal trial design.

At recent prices Madrigal sports a $3.5 billion market cap that could soar in the long run if MGL-3196 repeats previous observations without any safety issues, but investors need to understand that it could also come crashing down if there's any trouble with its lead candidate. There's nothing in the company's pipeline to fall back on.

Mid-stage results left no doubt that MGL-3196 lowers liver fat content for patients, but we still don't know a lot about the drug's safety profile. No troubling safety issues reared their ugly heads during the mid-stage study that propelled Madrigal into the spotlight, but there were only 107 patients in the trial.
https://finance.yahoo.com/news/3-top-stocks-investing-pharma-131700454.html

GO MDGL

"PEACE"